Antibiotics, Antineoplastic
"Antibiotics, Antineoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
| Descriptor ID |
D000903
|
| MeSH Number(s) |
D27.505.954.248.106
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibiotics, Antineoplastic".
Below are MeSH descriptors whose meaning is more specific than "Antibiotics, Antineoplastic".
This graph shows the total number of publications written about "Antibiotics, Antineoplastic" by people in this website by year, and whether "Antibiotics, Antineoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 0 | 3 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 2 | 4 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 3 | 1 | 4 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 2 | 3 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 3 | 3 |
| 2008 | 2 | 3 | 5 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 2 | 3 |
| 2013 | 3 | 2 | 5 |
| 2014 | 6 | 3 | 9 |
| 2015 | 5 | 2 | 7 |
| 2016 | 0 | 1 | 1 |
| 2017 | 3 | 1 | 4 |
| 2018 | 0 | 1 | 1 |
| 2019 | 4 | 2 | 6 |
| 2020 | 3 | 0 | 3 |
| 2021 | 3 | 2 | 5 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibiotics, Antineoplastic" by people in Profiles.
-
Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci. Pharmacogenomics J. 2024 Jun 29; 24(4):21.
-
Obesity Predisposes Anthracycline-Treated Survivors of Childhood and Adolescent Cancers to Subclinical Cardiac Dysfunction. Pediatr Cardiol. 2025 Feb; 46(2):362-371.
-
Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update. J Clin Oncol. 2024 May 01; 42(13):1472-1476.
-
Guidelines for Standardization of Pediatric Anthracycline Cardiomyopathy Echocardiogram Surveillance-A Call for Harmonization in the Field to Enhance Research in the Cancer Survivor Population. Pediatr Cardiol. 2024 02; 45(2):452-453.
-
Circulating microRNAs and Cytokines as Prognostic Biomarkers for Doxorubicin-Induced Cardiac Injury and for Evaluating the Effectiveness of an Exercise Intervention. Clin Cancer Res. 2023 11 01; 29(21):4430-4440.
-
Early skeletal muscle loss in adolescent and young adult cancer patients treated with anthracycline chemotherapy. Cancer Med. 2023 11; 12(22):20798-20809.
-
Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity. Int J Biol Sci. 2023; 19(14):4644-4656.
-
Anthracycline-induced cardiotoxicity - are we about to clear this hurdle? Eur J Cancer. 2023 05; 185:94-104.
-
Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. J Clin Oncol. 2023 04 20; 41(12):2248-2257.
-
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. J Clin Oncol. 2023 04 01; 41(10):1841-1848.